Lisata Therapeutics, Inc. filed an 8-K current report on November 19, 2026, disclosing that it filed a Certificate of Amendment to effect a one-for-fifteen reverse stock split of its common stock, with the split set to become effective at 12:01 a.m. Eastern Time on November 23, 2026.

Key Highlights

  • Reverse split ratio: The Board of Directors set the ratio at one-for-fifteen, within the stockholder-approved range of one-for-five to one-for-fifteen.
  • Effective time: The reverse stock split becomes effective at 12:01 a.m., Eastern Time, on November 23, 2026.
  • Stockholder approval: Stockholders approved the reverse split amendment at the Company's 2026 annual meeting held on November 9, 2026.
  • No fractional shares: Stockholders entitled to a fractional share will receive a cash payment equal to the fractional share interest multiplied by the closing price of the common stock on November 19, 2026.
  • New CUSIP: The new CUSIP number for the common stock following the reverse split is 128058 401.
  • Trading symbol unchanged: The common stock will continue to trade on The Nasdaq Capital Market under the symbol "LSTA" on a split-adjusted basis beginning at market open on November 23, 2026.

Lisata Therapeutics Executes 1-for-15 Reverse Split of Common Stock

According to the filing, Lisata Therapeutics, Inc. (NASDAQ:LSTA) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on November 19, 2026. The amendment effects a one-for-fifteen reverse stock split of the company's common stock, par value $0.001 per share. The company disclosed that every fifteen shares of common stock issued and outstanding immediately before the effective time will be combined into one share of common stock.

The filing states that the par value per share of common stock and the total number of authorized shares of common stock will remain unchanged as a result of the reverse stock split. The company also noted that the reverse stock split will not affect any stockholder's percentage ownership interest, "except for minor changes that may result from the treatment of fractional shares." Outstanding securities or rights convertible into, or exchangeable or exercisable for, the common stock will be adjusted for the reverse stock split in accordance with their terms, according to the filing.

The filing notes that stockholders approved the reverse split at the 2026 annual meeting held on November 9, 2026, authorizing the Board to set a ratio within the range of one-for-five to one-for-fifteen. The Board subsequently determined the final ratio of one-for-fifteen. The company issued a press release on November 19, 2026 announcing the reverse stock split, a copy of which was attached as Exhibit 99.1 to the current report. The filing contains forward-looking statements that are the company's own and subject to its cautionary language regarding risks and uncertainties.

What Was Disclosed

Lisata Therapeutics disclosed a one-for-fifteen reverse stock split of its common stock, effective November 23, 2026, following stockholder approval on November 9, 2026. Fractional shares will be settled in cash, and the new CUSIP number is 128058 401.